SCHEMBL21843232

SCHEMBL21843232

N#Cc1[nH]nnc1-c1ccc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.43
HPGD P15428 5/20 0.41
MAPT P10636 2/20 0.41
CNR1 P21554 7/20 0.40
CNR2 P34972 5/20 0.40
KDM4E B2RXH2 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
HSD11B1 P28845 1/20 0.39
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 2/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
ALOX12 P18054 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18004383 0.88 MARS1 (0.44) ALPLCNR1CNR2
SCHEMBL18005020 0.82 KDM4E (0.42) ALPLHPGDMAPTCNR1CNR2
SCHEMBL18005934 0.81 NPC1 (0.42) ALPLHPGDCNR1CNR2KDM4E
SCHEMBL18003741 0.80 CNR1 (0.41) ALPLHPGDMAPTCNR1CNR2
SCHEMBL18005061 0.80 SHMT1 (0.41) HPGDMAPTKDM4ETDP1HSD11B1
SCHEMBL18006102 0.80 ERBB2 (0.37) CNR1CNR2
SCHEMBL18005051 0.78 KDM4E (0.38) HPGDMAPTCNR1CNR2KDM4E
SCHEMBL18003962 0.77 CYP11B1 (0.37) HPGDCNR1CNR2ALDH1A1
SCHEMBL17969183 0.77 ERBB2 (0.49) HPGDKDM4EALDH1A1POLBNPSR1
SCHEMBL3354023 0.77 HPGD (0.45) ALPLHPGDMAPTKDM4EHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP claimed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 ALPL 1682/4885HPGD 2152/4885MAPT 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.